Plasma activity of of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever

Sonmez M., AYDIN K., DURMUS A., SUCU N., Yilmaz M., AKDOGAN E., ...More

JOURNAL OF INFECTION, vol.55, no.2, pp.184-187, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 2
  • Publication Date: 2007
  • Doi Number: 10.1016/j.jinf.2007.02.010
  • Journal Name: JOURNAL OF INFECTION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.184-187
  • Karadeniz Technical University Affiliated: Yes

Abstract

Objectives: Crimean-Congo hemorrhagic fever (CCHF) is a potentially fatal viral infection. The exact mechanism for hemorrhage remains unknown. Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma procarboxypeptidase B-like proenzyme and synthesized in the liver, down-regulating fibrinolysis. In this study, we measured the TAR activity in plasma of patients with CCHF to examine the relationship between hemorrhage and the pathogenesis of CCHF.